The SNMMI 2019 Annual Meeting wrapped up last week and proved to be an informative and eventful event. The Digirad team was on hand during the show and enjoyed connecting with colleagues and customers in Anaheim, California. Here are some highlights from SNMMI 2019.
Image of the Year & the Future of Theranostics
One of the big stories from the show was the announcement of the Image of the Year.
Each year, the SNMMI chooses an image that best exemplifies the most promising advances in the field of nuclear medicine. This year the award went to a team of researchers at University Hospital Heidelberg, Germany for a 68Ga-FAPI-PET/CT study.
While the image was impressive, the radiotracer used to deliver the image is what was making waves. The single radiotracer highlighted in the award can identify nearly 30 types of cancer and allows for new applications in noninvasive diagnosis, staging, and treatment.
The results of the study demonstrate that positron emission tomography/computed tomography (PET/CT) with a fibroblast-activation protein inhibitor (FAPI)—which targets the overexpressed proteins present in cancer—resulted in images with exceptionally clear tumor delineation and high image contrast
In this video from WebsEdgeHealth, Dr. Frederik Giesel discusses how the team created the image and what it means:
A Busy Week for Digirad
The Digirad team participated in several events at SNMMI 2019. Visitors were welcomed into the exhibit hall by Gypsy; our custom painted Ergo that is used for point-of-care imaging.
Exequiel Zaballero kicked off the Training Showcases on Sunday morning with an insightful presentation about Fluorescence Attenuation Correction. The presentation explained what SPECT FAC is, how it works, and why it matters.
While at the show we also took time to interview colleagues and industry insiders for a video series that will be debuting later in 2019. Watch the Digirad blog and our LinkedIn channel for more in the coming months.
New Officers for SNMMI
SNMMI also announced a new set of officers at the 2019 Annual Meeting.
Newly elected President Dr. Vasken Dilsizian stated, “Within a short period of time, we have witnessed the approval of several new diagnostic and therapeutic agents by the FDA, which was a tall order. More innovations are in development and clinical trials, with potentially huge impact for patients. SNMMI is ready to meet the challenge of guiding them to approval and appropriate reimbursement.”
The Digirad team congratulates all the new officers and looks forward to working with SNMMI over the next year to further the mission of nuclear medicine.